Cordes, 2020 - Google Patents
Targeted gene transfer to enhance safety and efficacy of immunotherapyCordes, 2020
View PDF- Document ID
- 7137775925953463977
- Author
- Cordes N
- Publication year
External Links
Snippet
The remarkable success of chimeric antigen receptor (CAR) T cell therapy in phase I/II trials resulted in market approval for the treatment of specific B cell malignancies. However, a considerable number of relapses were reported, for instance due to impaired T cell …
- 238000009169 immunotherapy 0 title abstract description 9
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hamilton et al. | In vivo human T cell engineering with enveloped delivery vehicles | |
| JP7216045B2 (en) | Central memory T cells for adoptive T cell therapy | |
| US12258574B2 (en) | Methods and compositions for transducing lymphocytes and regulating the activity thereof | |
| CN111479921B (en) | Methods and compositions for genetically modifying and expanding lymphocytes and modulating their activity | |
| Moffett et al. | Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers | |
| AU2018226884A1 (en) | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof | |
| US20230407330A1 (en) | Vector system for delivery of multiple polynucleotides and uses thereof | |
| AU2017292936A1 (en) | Methods and compositions for transducing lymphocytes and regulating the activity thereof | |
| IL253399B2 (en) | Modified hepatitis post-transcriptional regulatory element polynucleotides, compositions containing same and uses thereof | |
| JP2021500909A (en) | Adapter-based retroviral vector system for selective transduction of target cells | |
| CN117642420A (en) | Lipid particles containing truncated baboon endogenous retrovirus (BaEV) envelope glycoproteins and related methods and uses | |
| US20200397821A1 (en) | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof | |
| US20230392139A1 (en) | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof | |
| US20230398148A1 (en) | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods | |
| Cordes | Targeted gene transfer to enhance safety and efficacy of immunotherapy | |
| WO2024044557A1 (en) | Compositions and methods for targeted delivery of crispr-cas effector polypeptides | |
| Winter et al. | A novel pseudotype derived of the canine distemper virus for adapter-mediated lentiviral transduction in vivo | |
| WO2025184529A1 (en) | Viral particles with fusogen display and related compositions and methods | |
| WO2024119157A1 (en) | Lipid particles with cofusogens and methods of producing and using the same | |
| Fichter | Development of Novel Transient Delivery Systems for Gene Therapy | |
| US20220315894A1 (en) | Method for Transduction of T Cells in the Presence of Malignant Cells | |
| WO2024243340A1 (en) | Tandem fusogens and related lipid particles | |
| WO2024220560A1 (en) | Engineered protein g fusogens and related lipid particles and methods thereof | |
| CN119677772A (en) | Engineered stem cells and their uses | |
| HK1247046B (en) | Central memory t cells for adoptive t cell therapy |